Vivos Therapeutics Stock News

mmRNA is the first and only appliance of its kind covered by Medicare

HIGHLANDS RANCH, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercia

Vivos management to present at 1:55 pm Eastern Time on December 9, 2021 Vivos management to present at 1:55 pm Eastern Time on December 9, 2021

Zacks Investment Research cut shares of Vivos Therapeutics (NASDAQ:VVOS) from a hold rating to a sell rating in a research note released on Friday morning, Zacks.com reports. According to Zacks, Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising []

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest during the month of October. As of October 29th, there was short interest totalling 419,400 shares, an increase of 41.6% from the October 14th total of 296,200 shares. Approximately 3.1% of the companys stock are sold short. Based on an average []

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q3 2021 Results - Earnings Call Transcript

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results

Vivos management to present at 11:45 am Eastern Time on November 17, 2021 Vivos management to present at 11:45 am Eastern Time on November 17, 2021

HIGHLANDS RANCH, Colo., Oct. 19, 2021 /PRNewswire/ -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innov

HIGHLANDS RANCH, Colo., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commerciali

HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercial

Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collabo

Vivos management to present at 7:00 am EDT on September 13, 2021

Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.